Harvard Bioscience (HBIO) Research & Development (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Research & Development data on file, last reported at $2.3 million in Q1 2026.

• Quarterly Research & Development changed 0.22% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.8 million (down 10.28% YoY) and the FY2025 annual result came in at $8.8 million, down 15.19% from the prior year.
• Research & Development advanced to $2.3 million in Q1 2026 per HBIO's latest filing, from $2.2 million in the prior quarter.
• Across five years, Research & Development topped out at $3.5 million in Q2 2022 and bottomed at $2.1 million in Q3 2025.
• The 5-year median for Research & Development is $2.8 million (2023), against an average of $2.7 million.
• The widest annual swing landed in 2022, when Research & Development climbed 29.47%; it then retreated 26.1% in 2024.
• Tracing HBIO's Research & Development over 5 years: stood at $2.8 million in 2022, then increased by 10.57% to $3.2 million in 2023, then dropped by 26.1% to $2.3 million in 2024, then fell by 6.23% to $2.2 million in 2025, then grew by 6.55% to $2.3 million in 2026.
• Per Business Quant, the three latest HBIO Research & Development figures stand at $2.3 million (Q1 2026), $2.2 million (Q4 2025), and $2.1 million (Q3 2025).

Peer Comparison